PERSPECTIVE THERAPEUTICS, INC. financials

CATX CIK 0000728387

Source: EDGAR filings · Built 2026-06-03T02:25:07Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2023FY 2022FY 2021
Free Cash Flow -95.23M -72.71M -37.98M -10.68M -7.98M -3.22M
EBITDA -110.31M -88.58M -39.95M -8.40M -3.26M
Working Capital 119.71M 212.93M 1.17M 50.10M 57.06M 65.50M
Net Debt -27.32M -57.47M -6.64M -20.60M -55.37M -63.05M
Gross Margin 100.00% 0.00% 188.97%
Operating Margin -2855.02% -118.54% -127.16%
Net Margin -3243.24% -134.29% -124.98%
Return on Equity (ROE) -49.81% -27.27% -61.86% -19.69% -11.87% -5.02%
Return on Assets (ROA) -38.63% -23.24% -47.51% -18.52% -11.29% -4.81%
Current Ratio 5.17× 12.68× 1.07× 17.07× 26.18× 37.37×
Debt-to-Equity 0.02× 0.01× 0.03× 0.01× 0.01× 0.01×
Effective Tax Rate 0.76% 2.61% 6.61% 0.00% 0.00%
Cash Conversion Ratio 0.80× 0.23× 0.79× 0.97× 1.06× 0.84×
Accruals Ratio -0.08× -0.18× -0.10× -0.01× 0.01× -0.01×
SBC % of Revenue 260.67% 20.07% 14.24%
CapEx Coverage -6.47× -0.34× -34.43× -36.88× -28.98× -7.45×
Free Cash Flow Per Share $-1.29 $-1.13 $-1.42 $-0.08 $-0.05 $-0.03

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2023FY 2022FY 2021
P/S 7.86× 8.13× 41.89×
P/B 0.99× 0.78× 0.15× 0.65× 0.72× 1.68×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2023FY 2022FY 2021
Revenues 5.42M 2.71M
Cost of Goods and Services Sold 2.73M 6.18M 4.93M
Gross Profit 1.43M 0 0 5.12M
Research and Development Expense 84.22M 41.64M 21.31M 881.00K 850.00K 1.43M
Operating Expenses 114.45M 92.34M 42.38M 8.67M 6.42M 8.57M
Operating Income (Loss) -113.56M -90.89M -40.94M -8.67M -6.42M -3.45M
Income Tax Expense (Benefit) -793.00K -2.10M -2.65M 0 0 0
Net Income (Loss) Attributable to Parent -103.12M -79.28M -46.51M -10.76M -7.27M -3.39M
Earnings Per Share, Basic $-1.40 $-1.23 $-1.74 $-0.08 $-0.05 $-0.03
Weighted Average Number of Shares Outstanding, Basic 73.81M 64.42M 26.76M 142.07M 141.99M 103.84M
Earnings Per Share, Diluted $-1.40 $-1.23 $-1.74
Weighted Average Number of Shares Outstanding, Diluted 73.81M 64.42M 26.76M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 30.63M 61.58M 9.24M 20.99M 55.89M 63.83M
Assets, Current 148.39M 231.16M 16.84M 53.22M 59.33M 67.30M
Assets 266.97M 341.10M 97.89M 58.09M 64.44M 70.42M
Long-term Debt 1.63M 1.68M 1.73M
Liabilities, Current 28.68M 18.23M 15.66M 3.12M 2.27M 1.80M
Liabilities 59.94M 50.43M 22.71M 3.45M 3.16M 3.01M
Stockholders' Equity Attributable to Parent 207.03M 290.67M 75.18M 54.64M 61.28M 67.41M
Common Stock, Shares, Outstanding 74.34M 70.67M 28.18M 142.11M 142.04M 141.92M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities -82.48M -18.29M -36.91M -10.40M -7.71M -2.84M
Payments to Acquire Property, Plant, and Equipment 12.75M 54.41M 1.07M 282.00K 266.00K 381.00K
Net Cash Provided by (Used in) Investing Activities 41.23M -218.93M 24.37M -28.99M -284.00K -410.00K
Net Cash Provided by (Used in) Financing Activities 10.30M 289.38M 785.00K 28.00K 56.00K 64.68M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CATX CIK 0000728387), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

WMB

Williams Companies, Inc.

ENOV

Enovis Corp

NTIC

NORTHERN TECHNOLOGIES INTERNATIONAL CORPORATION